Newly approved MRI contrast agent Gadopiclenol set to boost short supply
The U.S Food and Drug Administration’s (FDA) recent approval of Gadopiclenol injection, a gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI), paves the way for a new marketing paradigm that is designed to ensure the broadest possible access to patients and their healthcare professionals in need of imaging agents.